Scientific Publications
Dr. Levy's work is documented in numerous peer-reviewed journal articles and issued/published patents.
Additionally, he has presented his work in various scientific forums.
Dr. Levy is both author and editor of several books covering sugar chemistry and organic reaction mechanisms.
Published Journal Articles and Book Chapters
Heterobifunctional PEGs: Efficient Synthetic Strategies and Useful Conjugation Methodologies. Daniel E. Levy; Brian Frederick; Bing Luo; Samuel Zalipsky; Bioorganic and Medicinal Chemistry Letters, 2010, 20, 6823-6826.
PEGylated Iminodiacetic Acid Zinc Complex Stabilizes Cationic RNA-Bearing Nanoparticles. Daniel E. Levy; Zhongli Ding; Chiwei Hu; Samuel Zalipsky; Bioorganic and Medicinal Chemistry Letters, 2010, 20, 5499-5501.
Financial Challenges and Shrinking Pipelines. Daniel E. Levy; European Biopharmaceutical Review, April 2010, 10-13, Invited Contribution.
Amide-Based Inhibitors of p38a MAP Kinase. Part 1: Discovery of Novel N-PyridylAmide Lead Molecules. Gregory R. Luedtke; Kurt Schinzel; Xuefei Tan; Richland W. Tester; Imad Nashashibi; Yong-jin Xu; Sundeep Dugar; Daniel E. Levy; Joon Jung; Bioorganic and Medicinal Chemistry Letters, 2010, 20, 2556-2559.
Amide-Based Inhibitors of p38a MAP Kinase. Part 2: Design, Synthesis and SAR of Potent N-pyrimidyl Amides. Richland Tester; Xuefei Tan; Gregory R. Luedtke; Imad Nashashibi; Kurt Schinzel; Weiling Liang; Joon Jung; Sundeep Dugar; Albert Liclican; Jocelyn Tabora; Daniel E. Levy; Steven Do; Bioorganic and Medicinal Chemistry Letters, 2010, 20, 2560-2563.
Piperidine-Based Heterocyclic Oxalyl Amides as Potent p38a MAP Kinase Inhibitors. Babu J. Mavunkel; John J. Perumattam; Xuefei Tan; Gregory R. Luedtke; Qing Lu; Don Lim; Darin Kizer; Sundeep Dugar; Sarvajit Chakravarty; Yong-jin Xu; Joon Jung; Albert Liclican; Daniel E. Levy; Jocelyn Tabora; Bioorganic and Medicinal Chemistry Letters, 2010, 20, 1059-1062.
Design and Synthesis of Piperazine-Indole p38a MAP Kinase Inhibitors with Improved Pharmacokinetic Profiles. Xuefei Tan; Richland W. Tester; Gregory R. Luedtke; Sarvajit Chakravarty; Babu J. Mavunkel; John J. Perumattam; Qing Lu; Imad Nashashibi; Joon Jung; Jie Hu; Albert Liclican; Ramona Almirez; Jocelyn Tabora; Vinh Tran; Maureen Laney; Daniel E. Levy; Sundeep Dugar; Bioorganic and Medicinal Chemistry Letters, 2010, 20, 828-831.
Aryl-Indolyl Maleimides as Inhibitors of CaMKIIδ. Part 1: SAR of the Aryl Region. Daniel E. Levy; Dan-Xiong Wang; Qing Lu; Zheng Chen; John Perumattam; Yong-jin Xu; Albert Liclican; Jeffrey Higaki; Hanmin Dong; Maureen Laney; Babu Mavunkel; Sundeep Dugar; Bioorganic and Medicinal Chemistry Letters, 2008, 18, 2390-2394.
Aryl-Indolyl Maleimides as Inhibitors of CaMKIIδ. Part 2: SAR of the Amine Tether. Daniel E. Levy; Dan-Xiong Wang; Qing Lu; Zheng Chen; John Perumattam; Yong-jin Xu; Jeffrey Higaki; Hanmin Dong; Albert Liclican; Maureen Laney; Babu Mavunkel; Sundeep Dugar; Bioorganic and Medicinal Chemistry Letters, 2008, 18, 2395-2398.
Aryl-Indolyl Maleimides as Inhibitors of CaMKIIδ. Part 3: Importance of the Indole Orientation. Qing Lu; Zheng Chen; John Perumattam; Dan-Xiong Wang; Weiling Liang; Yong-jin Xu; Steven Do; Llorente Bonaga; Jeffrey Higaki; Hanmin Dong; Albert Liclican; Steve Sideris; Maureen Laney; Sundeep Dugar; Babu Mavunkel; Daniel E. Levy; Bioorganic and Medicinal Chemistry Letters, 2008, 18, 2399-2403.
Pyrimidine-Based Inhibitors of CaMKIIδ. Babu Mavunkel; Yong-jin Xu; Bindu Goyal; Don Lim; Qing Lu; Zheng Chen; Dan-Xiong Wang; Jeffrey Higaki; Indrani Chakraborty; Albert Liclican; Steve Sideris; Maureen Laney; Ulrike Delling; Rosanne Catalano; Linda S. Higgins; Hui Wang; Jing Wang; Ying Feng; Sundeep Dugar; Daniel E. Levy; Bioorganic and Medicinal Chemistry Letters, 2008, 18, 2404-2408.
Type 2 Diabetes and Alzheimer’s Disease: From Common Pathologies to Potential new Therapeutics. Daniel E. Levy; Journal of Diabetes Science and Technology, 2007, 1(4), 590-594.
Functionalization of Sugars. Daniel E. Levy In The Organic Chemistry of Sugars. Daniel E. Levy, Ed; Peter Fugedi, Ed; CRC Press: Boca Raton, FL, 2005, pp 904.
Strategies towards C-Glycosides. Daniel E. Levy In The Organic Chemistry of Sugars. Daniel E. Levy, Ed; Peter Fugedi, Ed; CRC Press: Boca Raton, FL, 2005, pp 904.
Direct Inhibition of Type 5 Adenylyl Cyclase Prevents Myocardial Apoptosis without Functional Deterioration. Kousaku Iwatsubo; Susumu Minamisawa; Takashi Tsunematsu; Masamichi Nakagome; Yoshiyuki Toya; James E. Tomlinson; Satoshi Umemura; Robert M. Scarborough; Daniel E. Levy; Yoshihiro Ishikawa; Journal of Biological Chemistry, 2004, 279, 40938-40945.
Metal Coordination-Based Inhibitors of Adenylyl Cyclase: Novel Potent P-Site Antagonists. Daniel E. Levy; Ming Bao; Diana B. Cherbavaz; James E. Tomlinson; David M. Sedlock; Charles J. Homcy; Robert M. Scarborough; Journal of Medicinal Chemistry, 2003, 46, 2177-2186.
Hydroxamate Based Inhibitors of Adenylyl Cyclase (II): the Effect of Cyclic Linkers on P-Site Binding. Daniel E. Levy; Ming Bao; Jim Tomlinson; Robert M. Scarborough; Bioorganic and Medicinal Chemistry Letters, 2002, 12, 3089-3092.
Hydroxamate Based Inhibitors of Adenylyl Cyclase (I): the Effect of Acyclic Linkers on P-Site Binding. Daniel E. Levy; Charles Marlowe; Kim Kane-Maguire; Ming Bao; Diana Cherbavaz; Jim Tomlinson; David Sedlock; Robert M. Scarborough; Bioorganic and Medicinal Chemistry Letters, 2002, 12, 3085-3088.
Arterial Repair After Stenting and the Effects of GM6001, a MMP Inhibitor. Chris Li; Warren J. Cantor; Nafiseh Nili; Ranga Robinson; Louis Fenkall; Yen Le Tran; Heather A. Whittingham; Winston Tsui; Asim N. Cheema; John D. Sparkes; Kenneth Pritzker; Daniel E. Levy; Bradley H. Strauss; Journal of the American College of Cardiology, 2002, 39, 1852-1858.
Matrix Metalloproteinase Inhibitors: A Structure Activity Study. Daniel E. Levy; France Lapierre; Weisheng Liang; Wenqing Ye; Christopher W. Lange; Xiaoyuan Li; Damian Grobelny; Marie Casabonne; David Tyrrell; Kevin Holme; Alex Nadzan; Richard E. Galardy; Journal of Medicinal Chemistry, 1998, 41(2), 199-223.
Matrix Metalloproteinase Inhibitor Drugs. Daniel E. Levy; Alan M. Ezrin; Emerging Drugs: The Prospects for Improved Medicines, 1997, 2, 205-230.
Matrix Metalloproteinase Inhibitors Reduce Phorbol Ester Induced Cutaneous Inflammation and Hyperplasia. Walter Holleran; Richard E. Galardy; Wen Ni Gao; Daniel Levy; Peng Cho Tang; Peter M. Elias; Archives of Dermatological Research, 1997, 289(3), 138-144.
In-Vivo Collagen Turnover Following Experimental Balloon Angioplasty Injury and the Role of Matrix Metalloproteinases. Bradley H. Strauss; Ranga Robinson; Robert J. Chisholm; Grama Ravi; Madhu K. Natarajan; Shamir R. Mehta; Daniel E. Levy; Alan M. Ezrin; Richard A. Logan; Fred W. Keeley; Circulation Research, 1996, 79 (3), 541-550.
Glycomimetics as Selectin Inhibitors. John H. Musser; Mark B. Anderson; Daniel E. Levy; Current Pharmaceutical Design, 1995, 1, 221-232.
A Hydroxamic Acid Matrix Metalloprotease Inhibitor Blocks the Activity of Endothelin Converting Enzyme in Anesthetized Rats. Daniel E. Levy; Peng Cho Tang; Keri Sweet; Brent Summers; France LaPierre; Alan M. Ezrin; Med. Chem. Res. 1994, 4, 547-553.
Synthesis of Novel Fused Ring C-Glycosides. Daniel E. Levy; Falguni Dasgupta; Peng Cho Tang; Tetrahedron Asymmetry 1994, 5, 2265-2268, Invited Contribution.
Cell Adhesion and Carbohydrates. Daniel E. Levy; Peng Cho Tang; John H. Musser; Annual Reports in Medicinal Chemistry 1994, 29, 215-224, Invited Contribution.
Towards the Synthesis of Calyculin: A Synthetic Intermediate Corresponding to the C(26)-C(37) Fragment. Henry A. Vaccaro; Daniel E. Levy; Akiyoshi Sawabe; Thomas Jaetsch; Satoru Masamune; Tetrahedron Let. 1992, 33, 1937-1940.
Spectroscopic Determination of the Second Dissociation Constant of H2Se and the Activity Coefficients and Spectral Shifts of Its Ions. Daniel E. Levy; Rollie J. Myers; J. Phys. Chem. 1990, 94, 7842-7847.
COMMUNICATIONS
Copyright Daniel E. Levy, All Rights Reserved